Emisphere Technologies, Inc. (EMIS) is a specialty pharmaceutical company that recently commenced commercial operations. The company launched its first prescription product, oral Eligen B12, in the U.S. in March 2015. Beyond Eligen B12, the company utilizes its proprietary Eligen(R) Technology to create new oral formulations of therapeutic agents. Emisphere is currently partnered with global pharmaceutical companies for the development of new, orally delivered therapeutics. For more information, visit the company’s website at www.emisphere.com